Compare Merck & Co., Inc. (MRK) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Strategy Inc. — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Strategy Inc. trades at $131.28 (market cap $54.24B). The key difference: Merck & Co., Inc. is far larger — about 6.7× Strategy Inc.'s market cap, and Merck & Co., Inc. pays a 2.3% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| MRK | MSTR | |
|---|---|---|
Market Cap | $363.98B | $54.24B |
Sector | Health | Technology |
52-Week High | $156.43 | $359.69 |
52-Week Low | $77.60 | $82.31 |
Enterprise Value | $410.75B | $73.00B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
MSTR trades at $136.52, down 4.4% today, with a bullish technical signal from moving averages and support at $135. The company reported Q2 2026 EPS of -$24.45, missing expectations, and has a negative net income margin of -6,102.96%. Recent news highlights MSTR's partnership with Google Cloud for AI forums and a shift in capital allocation toward preferred stock buybacks instead of Bitcoin purchases.
Outlook remains speculative with high volatility; analyst consensus is bullish with a $229.64 price target, but risks include persistent earnings misses, heavy debt, and dependence on Bitcoin's performance. Institutional sentiment is mixed amid operational cash flow challenges and competitive pressures in software services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
